Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33150513" target="_blank" >RIV/61989592:15110/14:33150513 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.2217/IMT.14.50" target="_blank" >http://dx.doi.org/10.2217/IMT.14.50</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2217/IMT.14.50" target="_blank" >10.2217/IMT.14.50</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer

Popis výsledku v původním jazyce

Tumors in about 15% of patients with breast cancer overexpress HER2. Trastuzumab (Herceptin (R); F. Hoffmann-La Roche, Basel, Switzerland) is a humanized monoclonal antibody against HER2. While the introduction of trastuzumab has changed the natural course of HER2-positive breast cancer, the need for repeated administration of the drug over a prolonged period of time represents a challenge. Similarly to other chronic disorders, subcutaneous administration of monoclonal antibodies may be of advantage inthis setting. The results of a prospective randomized Phase III study have demonstrated that subcutaneous trastuzumab is noninferior compared with the intravenous administration of the drug in terms of efficacy (assessed as pathological complete responserate) as well as in pharmacokinetic parameters. Moreover, another prospective randomized study showed that an overwhelming majority of patients prefer subcutaneous over intravenous trastuzumab. The advent of subcutaneous trastuzumab repr

Název v anglickém jazyce

Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer

Popis výsledku anglicky

Tumors in about 15% of patients with breast cancer overexpress HER2. Trastuzumab (Herceptin (R); F. Hoffmann-La Roche, Basel, Switzerland) is a humanized monoclonal antibody against HER2. While the introduction of trastuzumab has changed the natural course of HER2-positive breast cancer, the need for repeated administration of the drug over a prolonged period of time represents a challenge. Similarly to other chronic disorders, subcutaneous administration of monoclonal antibodies may be of advantage inthis setting. The results of a prospective randomized Phase III study have demonstrated that subcutaneous trastuzumab is noninferior compared with the intravenous administration of the drug in terms of efficacy (assessed as pathological complete responserate) as well as in pharmacokinetic parameters. Moreover, another prospective randomized study showed that an overwhelming majority of patients prefer subcutaneous over intravenous trastuzumab. The advent of subcutaneous trastuzumab repr

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13564" target="_blank" >NT13564: Prediktivní faktory patologické odpovědi na neoadjuvantní chemoterapii u nemocných s karcinomem prsu a HER-2 pozitivním nebo triple negativním fenotypem</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Immunoterapy

ISSN

1750-743X

e-ISSN

—

Svazek periodika

6

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

811-819

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—